Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation

O’Connell, Grant; Petrone, Ashley; Tennant, Connie S.; Lucke-Wold, Noelle; Kabbani, Yasser; Tarabishy, Abdul; Chantler, Paul D.; Barr, Taura L.

doi:10.1080/02699052.2017.1312018

Cited by 52 publications

(47 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACS is a term encompassing clinical disorders of myocardial ischemia or infarction, and it has been demonstrated that inflammatory responses involving neutrophil activation play a major role in atherosclerotic changes and progression . According to a recent study, circulating extracellular DNA levels in AIS patients are associated with innate immune system activation . Though clear mechanisms are yet to be explored, these processes could lead to the elevated level of NETs in the ACS and AIS groups in this study.…”

Section: Discussionmentioning

confidence: 74%

Evaluation of neutrophil extracellular traps as the circulating marker for patients with acute coronary syndrome and acute ischemic stroke

Lim

Jeong

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Introduction:Neutrophil extracellular traps (NETs) are known to be induced by various factors. In this study, we tried to identify circulating levels of NETs in patients with acute coronary syndrome (ACS) and acute ischemic stroke (AIS) and to confirm its suitability as a new circulating marker in their detection. Methods:We prospectively enrolled 95 patients with a diagnosis of ACS (N = 37) or AIS (N = 58) in Dong-A University Hospital, Busan, Korea. The control group was selected from healthy adults (N = 25) who visited the hospital for health screening.Circulating levels of NETs were evaluated by measuring plasma concentrations of double-stranded DNA (dsDNA) and DNA-histone complex. Results:The concentrations of dsDNA were statistically higher in patients with ACS or AIS than those in the control group (both P < .001). In the univariable and multivariable analyses, statistically significant risk factors were troponin I (TnI) level and dsDNA concentration in the ACS group (P = .046 and P = .015, respectively) and only dsDNA concentration in the AIS group (P = .002). In the receiver operating characteristic curve analyses, the area under the curve values for TnI level and dsDNA concentration in the ACS group were 0.878 and 0.968, respectively, and the value for dsDNA concentration in the AIS group was 0.859.

show abstract

Section: Discussionmentioning

confidence: 74%

Evaluation of neutrophil extracellular traps as the circulating marker for patients with acute coronary syndrome and acute ischemic stroke

Lim

Jeong

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…33,34 Elevated cfDNA might also reflect physiological (e.g., exercise) 35,36 and non-malignant pathological processes, 7 such as inflammation, diabetes, tissue trauma, sepsis, and myocardial infarction. [37][38][39] The concentration of cfDNA in blood varies significantly; it ranges between 0-5 and >1000 ng/ml in patients with cancer and between 0 and 100 ng/ml in healthy subjects. 7,24 There is also a marked variation in blood ctDNA levels among patients with different tumor types.…”

Section: Introductionmentioning

confidence: 99%

“…97 Platelets induce NETosis by releasing thromboxane A2; then, in turn, NETosis leads to thrombin generation. 37,98 Lymphocytes, monocytes, and neutrophils can also release mtDNA strands. 93 In the blood, mtDNA can be present in both particle-associated and non-particle associated forms.…”

Section: Introductionmentioning

confidence: 99%

Life and death of circulating cell-free DNA

Kustanovich

Schwartz

Peretz

et al. 2019

Cancer Biology & Therapy

382

386

View full text Add to dashboard Cite

Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management. We will review the current understanding of the origin of circulating cell-free DNA and different forms of DNA release (including various types of cell death and active secretion processes) and clearance routes. The dynamics of extracellular DNA in blood during therapy and the role of circulating DNA in pathophysiological processes (tumor-associated inflammation, NETosis, and pre-metastatic niche development) provide insights into the mechanisms that contribute to tumor development and metastases formation. Better knowledge of circulating tumor-specific cell-free DNA could facilitate the development of new therapeutic and diagnostic options for cancer management. ARTICLE HISTORY

show abstract

“…As stated before, an increase in the quantity of cfDNA is not only seen in tumor patients but in other conditions as well. These are (just to mention a few examples) patients with myocardial infarction [150], an ischemic stroke [151], trauma patients [152] and healthy subjects who exercise extensively [153]. Additionally, it was demonstrated that the amount of cfDNA depends on many intrinsic as well as extrinsic factors (such as DNA extraction method, see following text) and that there is large overlap in the quantity of cfDNA in patients with a malignant or benign disease and frequently also with healthy people [154].…”

Section: Is Dna Quantification and Determination Of Cfdna Fragmentatimentioning

confidence: 99%

Pre-analytical issues in liquid biopsy – where do we stand?

Fleischhacker

Schmidt

2020

Journal of Laboratory Medicine

View full text Add to dashboard Cite

It is well documented that in the chain from sample to the result in a clinical laboratory, the pre-analytical phase is the weakest and most vulnerable link. This also holds for the use and analysis of extracellular nucleic acids. In this short review, we will summarize and critically evaluate the most important steps of the pre-analytical phase, i.e. the choice of the best control population for the patients to be analyzed, the actual blood draw, the choice of tubes for blood drawing, the impact of delayed processing of blood samples, the best method for getting rid of cells and debris, the choice of matrix, i.e. plasma vs. serum vs. other body fluids, and the impact of long-term storage of cell-free liquids on the outcome. Even if the analysis of cell-free nucleic acids has already become a routine application in the area of non-invasive prenatal screening (NIPS) and in the care of cancer patients (search for resistance mutations in the EGFR gene), there are still many unresolved issues of the pre-analytical phase which need to be urgently tackled.

show abstract

Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation

Cited by 52 publications

References 35 publications

Evaluation of neutrophil extracellular traps as the circulating marker for patients with acute coronary syndrome and acute ischemic stroke

Evaluation of neutrophil extracellular traps as the circulating marker for patients with acute coronary syndrome and acute ischemic stroke

Life and death of circulating cell-free DNA

Pre-analytical issues in liquid biopsy – where do we stand?

Contact Info

Product

Resources

About